Skip to main content
. 2023 Aug 1;24(1):2198479. doi: 10.1080/15384047.2023.2198479

Table 3.

Studies evaluating impact of pulmonary metastasectomy and other lung directed therapies.

Author Year Median age (years) Sample size Median Survival after Lung recurrence with Lung Directed Therapy Median OS with
Chemotherapy
(Months)		 Median OS with Lung Directed
Therapy
(Months)		 p-value
Downs-Canner et al.12 *
Robinson et al.14
Thomas et al.27
Arnaoutakis et al.28
Tagawa et al.29
Kurahara et al.30
Kim et al.31
Groot et al.27
Lovecek et al.32 		2015
2016
2012
2011
2017
2019
2019
2019
2017		 NR
61.5
61.7
31
72
72
NR
68
NR		 41
16
7
9
10
33
23
96
3		 NR
NR
NR
18.6
38.5
NR
36.5
35.0
12		 33.8
NR
NR
23
NR
16.4
NR
34.2
NR		 67.5
28
92.3
51
66.2
36.5
NR
68.9
NR		 0.006
NR
NR
0.04
NR
0.025
0.01**
<0.001***
NR

NR: Not Reported. *Study included patient who had lung resection, SBRT and other lung directed therapies. **Lung resection compared with palliative chemotherapy. ***Lung resection compared to palliative chemotherapy and or radiotherapy.